CPOPC: The price of palm oil is expected to fluctuate in the range of RM 4,000-5,000 in 2025. It is reported that the Council of Palm Oil Producers (CPOPC) predicts that the price of palm oil may fluctuate in the range of RM 4,000-5,000 per ton in 2025, driven by the stagnant production in major markets, especially Indonesia and Malaysia. Deputy Secretary-General CPOPC pointed out that the current price level around RM5,000 per ton may be temporary, mainly affected by the continuous floods in Malaysia, which boosted the bullish sentiment in the market. Due to the aging plantations, unpredictable weather and limited expansion to new plantations, it is expected that the cessation of production will tighten global supply and further push up prices.Gorgeous family: Nanjiang Group, the controlling shareholder, now holds 114 million shares of the company, accounting for 7.12% of the company's total share capital. Gorgeous family issued a notice of change, prompting the risk of share pledge. As of the disclosure date of this announcement, Nanjiang Group, the controlling shareholder of the company, now holds 114 million shares of the company, accounting for 7.12% of the company's total share capital. As of the disclosure date of this announcement, Nanjiang Group has pledged 90,075,800 shares of the company it holds, accounting for 5.62% of the company's total share capital and 79.00% of its total shares.India's new central bank governor: policy stability is very important and will try to maintain policy continuity.
Kremlin: (When asked whether the fall of Assad weakened Russia's influence in the Middle East) Military action in Ukraine is a top priority.Kremlin: Many people predict that Biden's administration will try to leave a difficult legacy by escalating tensions with Russia.The Shanghai Stock Exchange approved the refinancing of Dizhe Medicine to support the development of new quality productivity. The announcement of Dizhe Medicine shows that the private placement plan of Dizhe Medicine in science and technology innovation board has been approved by the Shanghai Stock Exchange. This is the first time that the refinancing of unprofitable enterprises in Shanghai Stock Exchange has been approved since the issuance of the Eight Measures on Deepening science and technology innovation board's Reform, Service, Scientific and Technological Innovation and Development of New Productivity by CSRC. As a listed company with the fifth standard in science and technology innovation board, Dizhe Medicine's refinancing has been approved by Shanghai Stock Exchange, which reflects the institutional inclusiveness and support of the capital market for supporting new quality productivity and unprofitable technology-based enterprises with key core technologies, great market potential and outstanding scientific and technological attributes. Dizhe Medicine said that the company's refinancing will help the company to further accelerate product research and development and production base construction, create new quality productivity, implement major national strategies, promote products to the sea, and give scientific and technological impetus to the development of biomedical economy. (Sina Technology)
Market News: US Secretary of State Blinken will travel to Jordan and Turkey for talks on the Syrian issue on Wednesday.Broadcom US stocks rose 3.6% before the market, while Apple US stocks rose 0.3% before the market. In the news, Apple is cooperating with Broadcom around artificial intelligence (AI) chips.Jinfei Kaida: The controlling shareholder plans to increase the company's shares by 50 million yuan to 100 million yuan. Jinfei Kaida announced that the controlling shareholder Jinfei Holdings plans to increase the company's shares by 50 million yuan to 100 million yuan. Jinhua Branch of China Construction Bank Co., Ltd. issued the "China Construction Bank Loan Commitment Letter" to Jinfei Holdings on December 10th, promising to provide Jinfei Holdings with a special loan of no more than 90 million yuan for stock increase, with a loan period of 3 years.
Strategy guide
12-13
Strategy guide 12-13
Strategy guide 12-13
Strategy guide 12-13
Strategy guide 12-13
Strategy guide 12-13